60 related articles for article (PubMed ID: 28482218)
1. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
[TBL] [Abstract][Full Text] [Related]
2. Rational design of peptide inhibitors targeting HSP90-CDC37 protein-protein interaction.
Zhang Q; Yan L; Zhang Y; Zhang L; Yu J; You Q; Wang L
Future Med Chem; 2024 Jan; 16(2):125-138. PubMed ID: 38189168
[No Abstract] [Full Text] [Related]
3. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S30. PubMed ID: 21342561
[TBL] [Abstract][Full Text] [Related]
4. Characterization of celastrol to inhibit hsp90 and cdc37 interaction.
Zhang T; Li Y; Yu Y; Zou P; Jiang Y; Sun D
J Biol Chem; 2009 Dec; 284(51):35381-9. PubMed ID: 19858214
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors.
Garg G; Zhao H; Blagg BS
Bioorg Med Chem; 2017 Jan; 25(2):451-457. PubMed ID: 27914946
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 inhibitors, part 2: combining ligand-based and structure-based approaches for virtual screening application.
Caroli A; Ballante F; Wickersham RB; Corelli F; Ragno R
J Chem Inf Model; 2014 Mar; 54(3):970-7. PubMed ID: 24555544
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.
Kusuma BR; Duerfeldt AS; Blagg BS
Bioorg Med Chem Lett; 2011 Dec; 21(23):7170-4. PubMed ID: 22014546
[TBL] [Abstract][Full Text] [Related]
8. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors.
Garg G; Forsberg LK; Zhao H; Blagg BSJ
Chemistry; 2017 Nov; 23(65):16574-16585. PubMed ID: 28940589
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity.
Zhang Z; Banerjee M; Davis RE; Blagg BSJ
Bioorg Med Chem Lett; 2019 Nov; 29(22):126676. PubMed ID: 31591016
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives.
Sellers RP; Alexander LD; Johnson VA; Lin CC; Savage J; Corral R; Moss J; Slugocki TS; Singh EK; Davis MR; Ravula S; Spicer JE; Oelrich JL; Thornquist A; Pan CM; McAlpine SR
Bioorg Med Chem; 2010 Sep; 18(18):6822-56. PubMed ID: 20708938
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of di-sansalvamide A derivatives: synthesis, structure-activity relationship, and mechanism of action.
Alexander LD; Sellers RP; Davis MR; Ardi VC; Johnson VA; Vasko RC; McAlpine SR
J Med Chem; 2009 Dec; 52(24):7927-30. PubMed ID: 20014866
[TBL] [Abstract][Full Text] [Related]
12. Novel Small Molecule Hsp90/Cdc37 Interface Inhibitors Indirectly Target K-Ras-Signaling.
Siddiqui FA; Parkkola H; Vukic V; Oetken-Lindholm C; Jaiswal A; Kiriazis A; Pavic K; Aittokallio T; Salminen TA; Abankwa D
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672199
[TBL] [Abstract][Full Text] [Related]
13. Discovery of the small molecular inhibitors against sclerostin loop3 as potential anti-osteoporosis agents by structural based virtual screening and molecular design.
Yu S; Huang W; Zhang H; Guo Y; Zhang B; Zhang G; Lei J
Eur J Med Chem; 2024 May; 271():116414. PubMed ID: 38677061
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of 4-(2-hydroxypropyl)piperazin-1-yl) derivatives as Hsp90 inhibitors.
Cherfaoui B; Guo TK; Sun HP; Cheng WL; Liu F; Jiang F; Xu XL; You QD
Bioorg Med Chem; 2016 Jun; 24(11):2423-2432. PubMed ID: 27134115
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
Goode KM; Petrov DP; Vickman RE; Crist SA; Pascuzzi PE; Ratliff TL; Davisson VJ; Hazbun TR
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1992-2006. PubMed ID: 28495207
[TBL] [Abstract][Full Text] [Related]
16. How Hsp90 and Cdc37 Lubricate Kinase Molecular Switches.
Verba KA; Agard DA
Trends Biochem Sci; 2017 Oct; 42(10):799-811. PubMed ID: 28784328
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer.
Wang L; Zhang L; Li L; Jiang J; Zheng Z; Shang J; Wang C; Chen W; Bao Q; Xu X; Jiang Z; Zhang J; You Q
Sci Adv; 2019 Sep; 5(9):eaax2277. PubMed ID: 31555737
[TBL] [Abstract][Full Text] [Related]
18. Microbial-Catalyzed Baeyer-Villiger Oxidation for 3,4-
Shen P; Zhou J; Jiang X; Ge H; Wang W; Yu B; Zhang J
ACS Omega; 2022 Jun; 7(22):18745-18751. PubMed ID: 35694476
[TBL] [Abstract][Full Text] [Related]
19. Targeting Chaperone/Co-Chaperone Interactions with Small Molecules: A Novel Approach to Tackle Neurodegenerative Diseases.
Wang L; Bergkvist L; Kumar R; Winblad B; Pavlov PF
Cells; 2021 Sep; 10(10):. PubMed ID: 34685574
[TBL] [Abstract][Full Text] [Related]
20. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity.
Cheng CJ; Liu KX; Zhang M; Shen FK; Ye LL; Wu WB; Hou XT; Hao EW; Hou YY; Bai G
Acta Pharmacol Sin; 2022 Apr; 43(4):1046-1058. PubMed ID: 34326484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
